Global HIV Therapy Market

HIV Therapy Comprehensive Study by Diagnosis (Antigen Tests, Antibody Tests, Nucleic Acid Tests (NATs)), Symptoms (Fever, Headache, Muscle Aches And Joint Pain, Rash) Players and Region - Europe Market Outlook to 2030

HIV Therapy Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About HIV Therapy
HIV treatment entails taking highly effective antiretroviral therapy (ART) medications that work to control the virus. ART is recommended for all HIV patients, and people with HIV should begin ART as soon as possible after diagnosis, if possible on the same day. People on ART use an HIV treatment regimen, which is a combination of HIV medications. A person's initial HIV treatment regimen typically consists of three HIV medicines from at least two different HIV drug classes, all of which must be taken exactly as prescribed. There are several options that combine two or three different HIV medications into a single once-daily pill. Long-acting HIV injections, given every two months, are also available if a health care provider determines that user meet certain criteria.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analyst at AMA Research estimates that United Kingdom Players will contribute the maximum growth to Europe HIV Therapy market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

GlaxoSmithKline plc. (United Kingdom), Abbott (United States), ViiV Healthcare (Australia), Pfizer Inc. (United States), Sanofi (France) and Gilead Sciences, Inc. (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Novartis AG (Switzerland) and Bristol-Myers Squibb Company (United States).

Segmentation Overview
AMA Research has segmented the market of Europe HIV Therapy market by and Region.



On the basis of geography, the market of HIV Therapy has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Diagnosis, the sub-segment i.e. Antigen Tests will boost the HIV Therapy market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Symptoms, the sub-segment i.e. Fever will boost the HIV Therapy market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Strong R&D Initiatives From Key Companies Are All Driving HIV Therapy and Technology developments in sample processing of HIV

Market Growth Drivers:
The Rising Geriatric Population Worldwide and Growing Awareness Regarding Health Among Individuals

Challenges:
Stringent Regulations, And Long Product Approval Process and Challenges To Develop HIV Therapy Products

Restraints:
Side Effect Associated With HIV Treatment and Lack Of Awareness Regarding The Available Treatment Options

Opportunities:
Rising Healthcare Expenditure and Government Favorable Incentives For HIV Treatment

Market Leaders and their expansionary development strategies
In January 2024. Sanofi and Inhibrx, Inc. a publicly traded clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates, have entered into a definitive agreement under which Sanofi has agreed to acquire Inhibrx following the spin-off of non-INBRX-101 assets into New Inhibrx. INBRX-101 is a human recombinant protein that holds the promise of allowing Alpha-1 Antitrypsin Deficiency (AATD) patients to achieve normalization of serum AAT levels with less frequent (monthly vs. weekly) dosing
In 2021, the Food and Drug Administration (FDA) approved Cabenuva, which contains two different types of HIV drugs: cabotegravir and rilpivirine. take it as an injection once a month at the doctor’s office. It makes a much easier option for people who find it hard to remember to take their pills every day.


Key Target Audience
HIV Therapy, New Entrants and Investors, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Diagnosis
  • Antigen Tests
  • Antibody Tests
  • Nucleic Acid Tests (NATs)

By Symptoms
  • Fever
  • Headache
  • Muscle Aches And Joint Pain
  • Rash

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. The Rising Geriatric Population Worldwide
      • 3.2.2. Growing Awareness Regarding Health Among Individuals
    • 3.3. Market Challenges
      • 3.3.1. Stringent Regulations, And Long Product Approval Process
      • 3.3.2. Challenges To Develop HIV Therapy Products
    • 3.4. Market Trends
      • 3.4.1. Strong R&D Initiatives From Key Companies Are All Driving HIV Therapy
      • 3.4.2. Technology developments in sample processing of HIV
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Europe HIV Therapy, by Diagnosis, Symptoms and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Europe HIV Therapy (Value)
      • 5.2.1. Europe HIV Therapy by: Diagnosis (Value)
        • 5.2.1.1. Antigen Tests
        • 5.2.1.2. Antibody Tests
        • 5.2.1.3. Nucleic Acid Tests (NATs)
      • 5.2.2. Europe HIV Therapy by: Symptoms (Value)
        • 5.2.2.1. Fever
        • 5.2.2.2. Headache
        • 5.2.2.3. Muscle Aches And Joint Pain
        • 5.2.2.4. Rash
      • 5.2.3. Europe HIV Therapy Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Australia
          • 5.2.3.2.6. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
  • 6. HIV Therapy: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. GlaxoSmithKline plc. (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Abbott (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. ViiV Healthcare (Australia)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Pfizer Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Sanofi (France)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Gilead Sciences, Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
  • 7. Europe HIV Therapy Sale, by Diagnosis, Symptoms and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Europe HIV Therapy (Value)
      • 7.2.1. Europe HIV Therapy by: Diagnosis (Value)
        • 7.2.1.1. Antigen Tests
        • 7.2.1.2. Antibody Tests
        • 7.2.1.3. Nucleic Acid Tests (NATs)
      • 7.2.2. Europe HIV Therapy by: Symptoms (Value)
        • 7.2.2.1. Fever
        • 7.2.2.2. Headache
        • 7.2.2.3. Muscle Aches And Joint Pain
        • 7.2.2.4. Rash
      • 7.2.3. Europe HIV Therapy Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Australia
          • 7.2.3.2.6. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. HIV Therapy: by Diagnosis(USD Million)
  • Table 2. HIV Therapy Antigen Tests , by Region USD Million (2018-2023)
  • Table 3. HIV Therapy Antibody Tests , by Region USD Million (2018-2023)
  • Table 4. HIV Therapy Nucleic Acid Tests (NATs) , by Region USD Million (2018-2023)
  • Table 5. HIV Therapy: by Symptoms(USD Million)
  • Table 6. HIV Therapy Fever , by Region USD Million (2018-2023)
  • Table 7. HIV Therapy Headache , by Region USD Million (2018-2023)
  • Table 8. HIV Therapy Muscle Aches And Joint Pain , by Region USD Million (2018-2023)
  • Table 9. HIV Therapy Rash , by Region USD Million (2018-2023)
  • Table 10. South America HIV Therapy, by Country USD Million (2018-2023)
  • Table 11. South America HIV Therapy, by Diagnosis USD Million (2018-2023)
  • Table 12. South America HIV Therapy, by Symptoms USD Million (2018-2023)
  • Table 13. Brazil HIV Therapy, by Diagnosis USD Million (2018-2023)
  • Table 14. Brazil HIV Therapy, by Symptoms USD Million (2018-2023)
  • Table 15. Argentina HIV Therapy, by Diagnosis USD Million (2018-2023)
  • Table 16. Argentina HIV Therapy, by Symptoms USD Million (2018-2023)
  • Table 17. Rest of South America HIV Therapy, by Diagnosis USD Million (2018-2023)
  • Table 18. Rest of South America HIV Therapy, by Symptoms USD Million (2018-2023)
  • Table 19. Asia Pacific HIV Therapy, by Country USD Million (2018-2023)
  • Table 20. Asia Pacific HIV Therapy, by Diagnosis USD Million (2018-2023)
  • Table 21. Asia Pacific HIV Therapy, by Symptoms USD Million (2018-2023)
  • Table 22. China HIV Therapy, by Diagnosis USD Million (2018-2023)
  • Table 23. China HIV Therapy, by Symptoms USD Million (2018-2023)
  • Table 24. Japan HIV Therapy, by Diagnosis USD Million (2018-2023)
  • Table 25. Japan HIV Therapy, by Symptoms USD Million (2018-2023)
  • Table 26. India HIV Therapy, by Diagnosis USD Million (2018-2023)
  • Table 27. India HIV Therapy, by Symptoms USD Million (2018-2023)
  • Table 28. South Korea HIV Therapy, by Diagnosis USD Million (2018-2023)
  • Table 29. South Korea HIV Therapy, by Symptoms USD Million (2018-2023)
  • Table 30. Australia HIV Therapy, by Diagnosis USD Million (2018-2023)
  • Table 31. Australia HIV Therapy, by Symptoms USD Million (2018-2023)
  • Table 32. Rest of Asia-Pacific HIV Therapy, by Diagnosis USD Million (2018-2023)
  • Table 33. Rest of Asia-Pacific HIV Therapy, by Symptoms USD Million (2018-2023)
  • Table 34. Europe HIV Therapy, by Country USD Million (2018-2023)
  • Table 35. Europe HIV Therapy, by Diagnosis USD Million (2018-2023)
  • Table 36. Europe HIV Therapy, by Symptoms USD Million (2018-2023)
  • Table 37. Germany HIV Therapy, by Diagnosis USD Million (2018-2023)
  • Table 38. Germany HIV Therapy, by Symptoms USD Million (2018-2023)
  • Table 39. France HIV Therapy, by Diagnosis USD Million (2018-2023)
  • Table 40. France HIV Therapy, by Symptoms USD Million (2018-2023)
  • Table 41. Italy HIV Therapy, by Diagnosis USD Million (2018-2023)
  • Table 42. Italy HIV Therapy, by Symptoms USD Million (2018-2023)
  • Table 43. United Kingdom HIV Therapy, by Diagnosis USD Million (2018-2023)
  • Table 44. United Kingdom HIV Therapy, by Symptoms USD Million (2018-2023)
  • Table 45. Netherlands HIV Therapy, by Diagnosis USD Million (2018-2023)
  • Table 46. Netherlands HIV Therapy, by Symptoms USD Million (2018-2023)
  • Table 47. Rest of Europe HIV Therapy, by Diagnosis USD Million (2018-2023)
  • Table 48. Rest of Europe HIV Therapy, by Symptoms USD Million (2018-2023)
  • Table 49. MEA HIV Therapy, by Country USD Million (2018-2023)
  • Table 50. MEA HIV Therapy, by Diagnosis USD Million (2018-2023)
  • Table 51. MEA HIV Therapy, by Symptoms USD Million (2018-2023)
  • Table 52. Middle East HIV Therapy, by Diagnosis USD Million (2018-2023)
  • Table 53. Middle East HIV Therapy, by Symptoms USD Million (2018-2023)
  • Table 54. Africa HIV Therapy, by Diagnosis USD Million (2018-2023)
  • Table 55. Africa HIV Therapy, by Symptoms USD Million (2018-2023)
  • Table 56. North America HIV Therapy, by Country USD Million (2018-2023)
  • Table 57. North America HIV Therapy, by Diagnosis USD Million (2018-2023)
  • Table 58. North America HIV Therapy, by Symptoms USD Million (2018-2023)
  • Table 59. United States HIV Therapy, by Diagnosis USD Million (2018-2023)
  • Table 60. United States HIV Therapy, by Symptoms USD Million (2018-2023)
  • Table 61. Canada HIV Therapy, by Diagnosis USD Million (2018-2023)
  • Table 62. Canada HIV Therapy, by Symptoms USD Million (2018-2023)
  • Table 63. Mexico HIV Therapy, by Diagnosis USD Million (2018-2023)
  • Table 64. Mexico HIV Therapy, by Symptoms USD Million (2018-2023)
  • Table 65. Company Basic Information, Sales Area and Its Competitors
  • Table 66. Company Basic Information, Sales Area and Its Competitors
  • Table 67. Company Basic Information, Sales Area and Its Competitors
  • Table 68. Company Basic Information, Sales Area and Its Competitors
  • Table 69. Company Basic Information, Sales Area and Its Competitors
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. HIV Therapy: by Diagnosis(USD Million)
  • Table 72. HIV Therapy Antigen Tests , by Region USD Million (2025-2030)
  • Table 73. HIV Therapy Antibody Tests , by Region USD Million (2025-2030)
  • Table 74. HIV Therapy Nucleic Acid Tests (NATs) , by Region USD Million (2025-2030)
  • Table 75. HIV Therapy: by Symptoms(USD Million)
  • Table 76. HIV Therapy Fever , by Region USD Million (2025-2030)
  • Table 77. HIV Therapy Headache , by Region USD Million (2025-2030)
  • Table 78. HIV Therapy Muscle Aches And Joint Pain , by Region USD Million (2025-2030)
  • Table 79. HIV Therapy Rash , by Region USD Million (2025-2030)
  • Table 80. South America HIV Therapy, by Country USD Million (2025-2030)
  • Table 81. South America HIV Therapy, by Diagnosis USD Million (2025-2030)
  • Table 82. South America HIV Therapy, by Symptoms USD Million (2025-2030)
  • Table 83. Brazil HIV Therapy, by Diagnosis USD Million (2025-2030)
  • Table 84. Brazil HIV Therapy, by Symptoms USD Million (2025-2030)
  • Table 85. Argentina HIV Therapy, by Diagnosis USD Million (2025-2030)
  • Table 86. Argentina HIV Therapy, by Symptoms USD Million (2025-2030)
  • Table 87. Rest of South America HIV Therapy, by Diagnosis USD Million (2025-2030)
  • Table 88. Rest of South America HIV Therapy, by Symptoms USD Million (2025-2030)
  • Table 89. Asia Pacific HIV Therapy, by Country USD Million (2025-2030)
  • Table 90. Asia Pacific HIV Therapy, by Diagnosis USD Million (2025-2030)
  • Table 91. Asia Pacific HIV Therapy, by Symptoms USD Million (2025-2030)
  • Table 92. China HIV Therapy, by Diagnosis USD Million (2025-2030)
  • Table 93. China HIV Therapy, by Symptoms USD Million (2025-2030)
  • Table 94. Japan HIV Therapy, by Diagnosis USD Million (2025-2030)
  • Table 95. Japan HIV Therapy, by Symptoms USD Million (2025-2030)
  • Table 96. India HIV Therapy, by Diagnosis USD Million (2025-2030)
  • Table 97. India HIV Therapy, by Symptoms USD Million (2025-2030)
  • Table 98. South Korea HIV Therapy, by Diagnosis USD Million (2025-2030)
  • Table 99. South Korea HIV Therapy, by Symptoms USD Million (2025-2030)
  • Table 100. Australia HIV Therapy, by Diagnosis USD Million (2025-2030)
  • Table 101. Australia HIV Therapy, by Symptoms USD Million (2025-2030)
  • Table 102. Rest of Asia-Pacific HIV Therapy, by Diagnosis USD Million (2025-2030)
  • Table 103. Rest of Asia-Pacific HIV Therapy, by Symptoms USD Million (2025-2030)
  • Table 104. Europe HIV Therapy, by Country USD Million (2025-2030)
  • Table 105. Europe HIV Therapy, by Diagnosis USD Million (2025-2030)
  • Table 106. Europe HIV Therapy, by Symptoms USD Million (2025-2030)
  • Table 107. Germany HIV Therapy, by Diagnosis USD Million (2025-2030)
  • Table 108. Germany HIV Therapy, by Symptoms USD Million (2025-2030)
  • Table 109. France HIV Therapy, by Diagnosis USD Million (2025-2030)
  • Table 110. France HIV Therapy, by Symptoms USD Million (2025-2030)
  • Table 111. Italy HIV Therapy, by Diagnosis USD Million (2025-2030)
  • Table 112. Italy HIV Therapy, by Symptoms USD Million (2025-2030)
  • Table 113. United Kingdom HIV Therapy, by Diagnosis USD Million (2025-2030)
  • Table 114. United Kingdom HIV Therapy, by Symptoms USD Million (2025-2030)
  • Table 115. Netherlands HIV Therapy, by Diagnosis USD Million (2025-2030)
  • Table 116. Netherlands HIV Therapy, by Symptoms USD Million (2025-2030)
  • Table 117. Rest of Europe HIV Therapy, by Diagnosis USD Million (2025-2030)
  • Table 118. Rest of Europe HIV Therapy, by Symptoms USD Million (2025-2030)
  • Table 119. MEA HIV Therapy, by Country USD Million (2025-2030)
  • Table 120. MEA HIV Therapy, by Diagnosis USD Million (2025-2030)
  • Table 121. MEA HIV Therapy, by Symptoms USD Million (2025-2030)
  • Table 122. Middle East HIV Therapy, by Diagnosis USD Million (2025-2030)
  • Table 123. Middle East HIV Therapy, by Symptoms USD Million (2025-2030)
  • Table 124. Africa HIV Therapy, by Diagnosis USD Million (2025-2030)
  • Table 125. Africa HIV Therapy, by Symptoms USD Million (2025-2030)
  • Table 126. North America HIV Therapy, by Country USD Million (2025-2030)
  • Table 127. North America HIV Therapy, by Diagnosis USD Million (2025-2030)
  • Table 128. North America HIV Therapy, by Symptoms USD Million (2025-2030)
  • Table 129. United States HIV Therapy, by Diagnosis USD Million (2025-2030)
  • Table 130. United States HIV Therapy, by Symptoms USD Million (2025-2030)
  • Table 131. Canada HIV Therapy, by Diagnosis USD Million (2025-2030)
  • Table 132. Canada HIV Therapy, by Symptoms USD Million (2025-2030)
  • Table 133. Mexico HIV Therapy, by Diagnosis USD Million (2025-2030)
  • Table 134. Mexico HIV Therapy, by Symptoms USD Million (2025-2030)
  • Table 135. Research Programs/Design for This Report
  • Table 136. Key Data Information from Secondary Sources
  • Table 137. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Europe HIV Therapy: by Diagnosis USD Million (2018-2023)
  • Figure 5. Europe HIV Therapy: by Symptoms USD Million (2018-2023)
  • Figure 6. South America HIV Therapy Share (%), by Country
  • Figure 7. Asia Pacific HIV Therapy Share (%), by Country
  • Figure 8. Europe HIV Therapy Share (%), by Country
  • Figure 9. MEA HIV Therapy Share (%), by Country
  • Figure 10. North America HIV Therapy Share (%), by Country
  • Figure 11. Europe HIV Therapy share by Players 2023 (%)
  • Figure 12. Europe HIV Therapy share by Players (Top 3) 2023(%)
  • Figure 13. BCG Matrix for key Companies
  • Figure 14. GlaxoSmithKline plc. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 15. GlaxoSmithKline plc. (United Kingdom) Revenue: by Geography 2023
  • Figure 16. Abbott (United States) Revenue, Net Income and Gross profit
  • Figure 17. Abbott (United States) Revenue: by Geography 2023
  • Figure 18. ViiV Healthcare (Australia) Revenue, Net Income and Gross profit
  • Figure 19. ViiV Healthcare (Australia) Revenue: by Geography 2023
  • Figure 20. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 21. Pfizer Inc. (United States) Revenue: by Geography 2023
  • Figure 22. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 23. Sanofi (France) Revenue: by Geography 2023
  • Figure 24. Gilead Sciences, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 25. Gilead Sciences, Inc. (United States) Revenue: by Geography 2023
  • Figure 26. Europe HIV Therapy: by Diagnosis USD Million (2025-2030)
  • Figure 27. Europe HIV Therapy: by Symptoms USD Million (2025-2030)
  • Figure 28. South America HIV Therapy Share (%), by Country
  • Figure 29. Asia Pacific HIV Therapy Share (%), by Country
  • Figure 30. Europe HIV Therapy Share (%), by Country
  • Figure 31. MEA HIV Therapy Share (%), by Country
  • Figure 32. North America HIV Therapy Share (%), by Country
List of companies from research coverage that are profiled in the study
  • GlaxoSmithKline plc. (United Kingdom)
  • Abbott (United States)
  • ViiV Healthcare (Australia)
  • Pfizer Inc. (United States)
  • Sanofi (France)
  • Gilead Sciences, Inc. (United States)
Additional players considered in the study are as follows:
Novartis AG (Switzerland) , Bristol-Myers Squibb Company (United States)
Select User Access Type

Key Highlights of Report


Mar 2024 200 Pages 57 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global HIV Therapy Market Quantitative research analysis
Global HIV Therapy Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as GlaxoSmithKline plc. (United Kingdom), Abbott (United States), ViiV Healthcare (Australia), Pfizer Inc. (United States), Sanofi (France) and Gilead Sciences, Inc. (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Strong R&D Initiatives From Key Companies Are All Driving HIV Therapy " is seen as one of major influencing trends for HIV Therapy Market during projected period 2023-2030.
The HIV Therapy market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global HIV Therapy Market Report?

Have a Query? Click Here

Other Related Reports

Virtual Urgent Care Comprehensive Study by Treatment (Allergies, Cough, Cold, & Flu, Eye Infections, Sore Throat (Adult Patients Only), Urinary Issues (Adult Patients Only), Minor Muscle Or Joint Pai...
$ 3500
Dulse Extracts Comprehensive Study by Application (Food & Beverages, Nutraceuticals, Retail/Household, Animal Feed, Cosmetics & Personal Care, Others), Form (Powder, Flakes, Liquid, Sheets), Distribu...
$ 3800
Kids Gym Franchise Service Comprehensive Study by Application (Gymnasium, Stadium, Other), Programs (Parent/Child, Pre-K/Kindergarten Gymnastics, Grade School Gymnastics, Dance, Karate, Sports Prepar...
$ 3800
Presbyopia Solutions Comprehensive Study by Application (Eye Disease Treatment, Eye Disease Diagnosis, Eye Surgery), Treatment Type (Eyeglasses, Contact Lenses, Refractive Surgery, Lens Implants, Cor...
$ 3800
Human Immune Health Supplement Comprehensive Study by Type (Vitamin C, Vitamin D, Zinc, Selenium, Iron, Protein, Others), Application (Hospital, Clinic, Household, Others), Distribution Channel (Onli...
$ 3800
Fluorescence-Guided Surgery System Comprehensive Study by Type (PDE system, VS3 iridium system, SPY system, Others), Application (Sentinel Lymph Node (SLN) Mapping, Identification of Solid Tumors, Ly...
$ 3500